Why Bicycle Therapeutics Stock Is Soaring Today
Bicycle Therapeutics plc (NASDAQ:BCYC) has announced interim Phase 1 results from the Phase 1/2 trial of BT8009, a second-generation BTC targeting Nectin-4, in patients with advanced solid tumors. The data will be presented at the 2022 American Association for Cancer Research Annual Meeting. Patients were treated until disease progression or intolerable toxicity, with…
Benzinga ·
Benzinga
